Humans, equinone, canine, bovine and other animals, and in particular, mammals, suffering from disorders mediated by PAG or products of 5-lipoxygenase can be treated by administering to the patient an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable derivative or salt thereof in a pharmaceutically acceptable carrier or diluent.